EntityRisk
Darius Lakdawalla currently holds the position of Quintiles Chair in Pharmaceutical Development and Regulatory Innovation at the University of Southern California since August 2009, where responsibilities include advancing innovative regulatory approaches in the pharmaceutical and healthcare sectors. Additionally, Darius serves as a Professor in the School of Pharmacy and the Price School of Public Policy and is the Director of Research at the Leonard D. Schaeffer Center for Health Policy and Economics, established with a significant donation in 2009. As a co-founder and Chief Scientific Officer of EntityRisk, Inc. and a founding partner of Precision Health Economics, Darius has contributed to developing data-driven solutions in health care and improving public policy. Previous experience includes serving as a Senior Economist and Director of Research at the Bing Center for Health Economics at the RAND Corporation. Darius earned a Ph.D. in Economics from the University of Chicago and a BA in Mathematics and Philosophy from Amherst College.
This person is not in any teams
This person is not in any offices
EntityRisk
EntityRisk's software enables healthcare innovators and payers to measure and manage uncertainty. EntityRisk was founded by three health economists— bringing together decades of academic and industry experience-- to unlock financial innovation in the way new medicines are brought to patients. EntityRisk is building a proprietary algorithmic library to better estimate individual benefits of treatment—through advanced modeling techniques and integrated clinical trial, genomic, and real-world data. Our growing, world-class team of economists, data scientists, software engineers, finance professionals and cutting-edge academic experts is building the tools needed to enable financial innovation in healthcare, some of which include: -Analysis of all current and potential surrogate measures and their connections to critical endpoints of value to patients and payers -Customized individual and subpopulation-level survival and treatment duration curves -Scenario planning for pipeline and inline assets -Proprietary event and cash flow forecasting and analytics for efficacy-linked instruments -Value modeling All of our models are specifically designed to identify risk characteristics and correlations across therapeutic interventions, enabling new value-based payment and performance guarantees.